There’s something brewing in New York biotech.
Call it a grass roots movement. No longer are the region’s scientists, non-profits, and entrepreneurs simply pounding the tables. They’re taking action. Institutions are banding together, forming initiatives hell bent on commercializing local research. Government-backed funds are teaming with local venture firms to put funds together to spur the creation of a startup culture in life sciences. Incubators are sprouting up. Local biotech innovators are leading the charge on a nimble style of dealmaking that’s caught the attention of the rest of the industry.
But who are these innovators, and what is their approach to building great biotechs locally, and seeing them grow and succeed? What areas of research is the region uniquely positioned to capitalize on? And how can the New York area finally take advantage of its financial might and industry presence, and be mentioned in the same breath as the buzzing biotech clusters in Boston and San Francisco?
Xconomy will be taking these issues head on at our latest event, “New York’s Life Science Disruptors,” on March 6 at the Apella event space at the Alexandria Center for Life Science on East 29th Street in Manhattan. We’ll be hosting an interactive night of discussion with some of the biggest disruptive forces in the local life sciences scene.
Here are some of the names you will see:
Marc Tessier-Lavigne: President of Rockefeller University, and a director of the New York Genome Center.
George Golumbeski: senior vice president of business development at Celgene.
Francois Nader: President and CEO of NPS Pharmaceuticals, and the chairman of BioNJ.
Alex Denner: Founding Partner of Sarissa Capital Management.
More details about the event and speakers are coming soon, but you can get your tickets here, and if you register by Feb. 6, you can take advantage of the early bird rate. Hope to see you at the Apella on March 6.
